Skip to content

Palonosetron vs Palonosetron And Dexamethasone In Reducing Postoperative Nausea And Vomiting After Laparoscopic Cholecystectomy

Comparison Of Palonosetron Versus Palonosetron With Dexamethasone In Prevention Of Postoperative Nausea And Vomiting After laparoscopic Cholecystectomy. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077677
Enrollment
100
Registered
2024-12-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Palonsetron injection: single dose of Palonsetron injection and check postoperative nausea and vomiting Control Intervention1: Palonsetron and dexamethasone injection: single dose of Pa

Sponsors

Dr Kondamuru Likhitha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: American Society of Anaesthesiologist Grade 1 & 2 Age between 18 and 60 years Patients posted for laparoscopic cholecystectomy

Exclusion criteria

Exclusion criteria: not willing to give consent age less than 18 yrs and more than 60yrs history of allergy to palonsetron and dexamethasone electrolyte abnormalities patient with drug history of SSRI and drugs which cause QT prolongation.

Design outcomes

Primary

MeasureTime frame
Primary objectives of this study is to assess the efficacy of monotherapy(palonosetron) vs combination therapy(palonosetron – dexamethasone) in preventing postoperative nausea and vomitingTimepoint: 2 years

Secondary

MeasureTime frame
Secondary objective is to study the number of rescue doses of antiemetics needed.Timepoint: 2 years

Countries

India

Contacts

Public ContactDr USSA Vara Prasad

Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation

doctorvaraprasad@gmail.com9849725560

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026